Stockreport

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

Abpro Holdings, Inc  (ABP) 
NASDAQ:AMEX Investor Relations: abpro.com/contact
PDF  IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profil [Read more]